Impaired high-density lipoprotein function and endothelial barrier stability in severe anaphylaxis
Por:
Fernandez-Bravo, S, Canyelles, M, Martín-Blázquez, A, Borràs, C, Nuñez-Borque, E, Palacio-García, L, Del Rio, PR, Betancor, D, Gómez-López, A, Brescó, MS, Laguna, JJ, Méndez-Barbero, N, Rotllan, N, Escolà-Gil, JC, Esteban, V
Publicada:
1 sep 2024
Ahead of Print:
1 sep 2024
Resumen:
Background: Growing evidence demonstrates the importance of high- and low-density lipoprotein cholesterol in certain immune and allergy-mediated diseases. Objective: This study aimed to evaluate levels of high- and low- density lipoprotein cholesterol and apolipoproteins A1 and B in sera from a cohort of patients presenting with hypersensitivity reactions. We further assessed the function of high-density lipoprotein particles as well as their involvement in the molecular mechanisms of anaphylaxis. Methods: Lipid profile determination was performed in paired (acute and baseline) serum samples from 153 patients. Thirtyeight experienced a non-anaphylactic reaction and 115 had an anaphylactic reaction (88 moderate and 27 severe). Lecithin cholesterol acyl transferase activity was assessed in patient sera, and we also evaluated macrophage cholesterol efflux in response to the serum samples. Last, the effect of anaphylactic-derived high-density lipoprotein (HDL) particles on the endothelial barrier was studied. Detailed methods are provided in the Methods section in this article's Online Repository available at www.jacionline.org. Results: Serum samples from severe anaphylactic reactions show statistically significant low levels of HDL cholesterol, low-density lipoprotein cholesterol, and apolipoproteins A1 and B, which points to their possible role as biomarkers. Specifically, HDL particles play a protective role in cardiovascular diseases. Using functional human serum cell assays, we observed impaired capacity of apolipoprotein B- depleted serum to induce macrophage cholesterol efflux in severe anaphylactic reactions. In addition, purified HDL particles from human anaphylactic sera failed to stabilize and maintain the endothelial barrier. Conclusion: These results encourage further research on HDL functions in severe anaphylaxis, which may lead to new diagnostic and therapeutic strategies.
Filiaciones:
Fernandez-Bravo, S:
Univ Autonoma Madrid IIS FJD, Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst, Dept Allergy & Immunol, Madrid, Spain
Canyelles, M:
Hospital Santa Creu & St Pau, Inst Invest Biomed St Pau, Inst Recerca, Barcelona, Spain
Inst Salud Carlos III, CIBER Diabet & Related Metab Dis, Madrid, Spain
Martín-Blázquez, A:
Univ Autonoma Madrid IIS FJD, Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst, Dept Allergy & Immunol, Madrid, Spain
Borràs, C:
Hospital Santa Creu & St Pau, Inst Invest Biomed St Pau, Inst Recerca, Barcelona, Spain
Inst Salud Carlos III, CIBER Diabet & Related Metab Dis, Madrid, Spain
Nuñez-Borque, E:
Univ Autonoma Madrid IIS FJD, Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst, Dept Allergy & Immunol, Madrid, Spain
Palacio-García, L:
Univ Autonoma Madrid IIS FJD, Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst, Dept Allergy & Immunol, Madrid, Spain
Del Rio, PR:
Hosp Infantil Univ Nino Jesu, Fdn HNJ, Hlth Res Inst Princesa, Allergy Dept, Madrid, Spain
Betancor, D:
Univ Autonoma Madrid FJD, Fdn Jimenez Diaz Univ Hosp, Dept Allergy, UAM, Madrid, Spain
Gómez-López, A:
Univ Autonoma Madrid FJD, Fdn Jimenez Diaz Univ Hosp, Dept Allergy, UAM, Madrid, Spain
Brescó, MS:
Clin Univ Navarra, Dept Allergy & Clin Immunol, Pamplona, Spain
Red Enfermedades Inflamatorias RD21-0002-0028, Pamplona, Spain
IDISNA Inst Invest Sanitaria Navarra, Hlth Res Inst, Pamplona, Spain
Laguna, JJ:
IDISNA Inst Invest Sanitaria Navarra, Hlth Res Inst, Pamplona, Spain
Cruz Roja Cent Hosp, Allergy Unit, Allergo Anaesthesia Unit, Madrid, Spain
Méndez-Barbero, N:
Univ Autonoma Madrid IIS FJD UAM, Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst, Vasc Pathol Res Lab, Madrid, Spain
Univ Alfonso X El Sabio UAX, Fac Med, Villanueva De La Canada, Spain
Rotllan, N:
Hospital Santa Creu & St Pau, Inst Invest Biomed St Pau, Inst Recerca, Barcelona, Spain
Inst Salud Carlos III, CIBER Diabet & Related Metab Dis, Madrid, Spain
Escolà-Gil, JC:
Hospital Santa Creu & St Pau, Inst Invest Biomed St Pau, Inst Recerca, Barcelona, Spain
Inst Salud Carlos III, CIBER Diabet & Related Metab Dis, Madrid, Spain
Esteban, V:
Univ Autonoma Madrid IIS FJD, Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst, Dept Allergy & Immunol, Madrid, Spain
Univ Alfonso X El Sabio UAX, Fac Med, Villanueva De La Canada, Spain
hybrid
|